**Data dictionary for data set: LK1601.LK1601share**

| **#** | **Variable** | **Description** | **Type** | **Value** | **Label** |
| --- | --- | --- | --- | --- | --- |
| 1 | **dummyid** | Dummy ID | Continuous |  |  |
| 2 | **dummyccn** | Dummy center number | Continuous |  |  |
| 3 | **strata** | Main effect: Flu/Mel vs. Flu/Bu | Categorical | 2 | FM |
|  |  |  |  | 3 | FB |
| 4 | **age** | Recipient age at HCT (continuous) | Continuous |  |  |
| 5 | **agegp** | Recipient age at HCT (categorical) | Categorical | 3 | 18-29 |
|  |  |  |  | 4 | 30-39 |
|  |  |  |  | 5 | 40-49 |
|  |  |  |  | 6 | 50-59 |
|  |  |  |  | 7 | 60-69 |
|  |  |  |  | 8 | 70+ |
| 6 | **sex** | Sex | Categorical | 1 | Male |
|  |  |  |  | 2 | Female |
| 7 | **kps** | Karnofsky score | Categorical | 0 | <90 |
|  |  |  |  | 1 | >=90 |
|  |  |  |  | 99 | Missing |
| 8 | **hctcigp** | HCT-CI | Categorical | 0 | 0 |
|  |  |  |  | 1 | 1 |
|  |  |  |  | 2 | 2 |
|  |  |  |  | 3 | 3+ |
|  |  |  |  | 98 | N/A, F2400 (pre-TED) not completed |
| 9 | **dxcr1gp** | Time from diagnosis to CR1 | Categorical | 1 | <=4 weeks |
|  |  |  |  | 2 | 4-8 weeks |
|  |  |  |  | 3 | >8 weeks |
|  |  |  |  | 4 | N/A, disease status not in CR1 |
|  |  |  |  | 99 | Missing |
| 10 | **amstatprgp** | Disease status prior to HCT | Categorical | 1 | Primary induction failure |
|  |  |  |  | 2 | CR1 |
|  |  |  |  | 3 | CR2+ |
|  |  |  |  | 5 | Relapse |
|  |  |  |  | 99 | Missing |
| 11 | **mrd** | MRD status prior to transplant | Categorical | 0 | Negative |
|  |  |  |  | 1 | Positive |
|  |  |  |  | 2 | Not CR1 |
|  |  |  |  | 98 | NA prior 2007 |
|  |  |  |  | 99 | Missing |
| 12 | **cytogene** | Cytogenetic score | Categorical | 2 | Favorable |
|  |  |  |  | 3 | Intermediate |
|  |  |  |  | 4 | Poor |
|  |  |  |  | 99 | Missing |
| 13 | **leuk2** | Therapy related/secondary AML | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
|  |  |  |  | 99 | Missing |
| 14 | **donorgp** | Donor type | Categorical | 1 | HLA-identical sibling |
|  |  |  |  | 3 | Other related |
|  |  |  |  | 4 | Well-matched unrelated |
|  |  |  |  | 5 | Partially-matched unrelated |
|  |  |  |  | 6 | Mis-matched unrelated |
|  |  |  |  | 8 | Unrelated matching unknown |
| 15 | **dnrage** | Donor age (continuous) | Continuous |  |  |
| 16 | **drsex** | Donor-recipient sex match | Categorical | 1 | M-M |
|  |  |  |  | 2 | M-F |
|  |  |  |  | 3 | F-M |
|  |  |  |  | 4 | F-F |
|  |  |  |  | 99 | Missing |
| 17 | **drcmvpr** | Donor-recipient CMV status | Categorical | 0 | +/+ |
|  |  |  |  | 1 | +/- |
|  |  |  |  | 2 | -/+ |
|  |  |  |  | 3 | -/- |
|  |  |  |  | 99 | Missing |
| 18 | **gvhdgpff** | GVHD prophylaxis | Categorical | 1 | TAC + MMF +- other(s) |
|  |  |  |  | 2 | TAC + MTX +- other(s) |
|  |  |  |  | 3 | TAC +/- Others (not MMF or MTX) |
|  |  |  |  | 4 | CSA + MMF +- other(s) |
|  |  |  |  | 5 | CSA + MTX +- other(s) |
|  |  |  |  | 6 | CSA +/- Others (not MMF or MTX) |
|  |  |  |  | 7 | Others |
|  |  |  |  | 99 | Missing |
| 19 | **atggrp** | ATG/alemtuxumab for conditioning regimen or GVHD prophylaxis | Categorical | 1 | Yes(ATG/Alemtuzumab) |
|  |  |  |  | 2 | No |
| 20 | **graftype** | Graft type | Categorical | 1 | BM |
|  |  |  |  | 22 | PB |
| 21 | **yearf** | Year of transplant | Categorical | 1 | 2001-2005 |
|  |  |  |  | 2 | 2006-2010 |
|  |  |  |  | 3 | 2011-2015 |
| 22 | **anc** | Neutrophil engraftment | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 23 | **platelet** | Platelet recovery | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 24 | **agvhd24** | Grade 2-4 acute GVHD | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 25 | **cgvhd** | Chronic GVHD | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 26 | **rel** | Relapse | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 27 | **trm** | Treatment related mortality | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 28 | **dfs** | Disease free survival | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 29 | **grfs** | GVHD-free, relapse-free survival | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 30 | **dead** | Death | Categorical | 0 | Censor |
|  |  |  |  | 1 | Event |
|  |  |  |  | 99 | Missing |
| 31 | **intxanc** | Time from HCT to neutrophil engraftment, months | Continuous |  |  |
| 32 | **intxplatelet** | Time from HCT to platelet recovery, months | Continuous |  |  |
| 33 | **intxagvhd24** | Time from HCT to 2-4 acute GVHD, months | Continuous |  |  |
| 34 | **intxcgvhd** | Time from HCT to chronic GVHD, months | Continuous |  |  |
| 35 | **intxrel** | Time from HCT to relapse, months | Continuous |  |  |
| 36 | **intxgrfs** | Time from HCT to GVHD-free, relapse-free survival, months | Continuous |  |  |
| 37 | **intxsurv** | Time from HCT to last follow-up / death | Continuous |  |  |